KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Depreciation and Depletion (2016 - 2021)

Arbutus Biopharma (ABUS) has disclosed Depreciation and Depletion for 7 consecutive years, with $427000.0 as the latest value for Q4 2021.

  • Quarterly Depreciation and Depletion fell 12.32% to $427000.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2021, down 11.38% year-over-year, with the annual reading at $363000.0 for FY2025, 73.7% down from the prior year.
  • Depreciation and Depletion hit $427000.0 in Q4 2021 for Arbutus Biopharma, down from $447000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $620000.0 in Q4 2017 to a low of $334000.0 in Q1 2017.
  • Historically, Depreciation and Depletion has averaged $498350.0 across 5 years, with a median of $500500.0 in 2020.
  • Biggest five-year swings in Depreciation and Depletion: skyrocketed 103.78% in 2017 and later dropped 18.71% in 2018.
  • Year by year, Depreciation and Depletion stood at $620000.0 in 2017, then dropped by 18.71% to $504000.0 in 2018, then rose by 0.6% to $507000.0 in 2019, then fell by 3.94% to $487000.0 in 2020, then dropped by 12.32% to $427000.0 in 2021.
  • Business Quant data shows Depreciation and Depletion for ABUS at $427000.0 in Q4 2021, $447000.0 in Q3 2021, and $436000.0 in Q2 2021.